IP Library › Granted Patent US 10,662,223
Granted Patent B2
US 10,662,223 · App. 15/307,632 · Granted May 26, 2020

Composition for organ, tissue, or cell transplantation, kit, and transplantation method

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GemVax & KAEL Co., Ltd.
C07K7/08A01N1/021C07K7/06C07K14/47C12N9/1276C12Y207/07049A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,662,223
App. No.
15/307,632
Granted
May 26, 2020
Kind
B2
Abstract

Disclosed are: a composition for organ, tissue or cell transplantation, containing, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1, a peptide having at least 80% sequence homology with the amino acid sequence, or a peptide which is a fragment thereof; a kit comprising the composition; or a method using the composition. By using the composition, the kit, or the method, the viability and/or function of an organ, tissue, or cell after transplantation are strengthened and an organ, tissue or cell isolated from a living body is preserved temporarily without damage.

Claims (14)

1. A method for organ, tissue or cell transplantation comprising isolating an organ, tissue or cell for transplantation from a donor; contacting the isolated organ, tissue or cells with the isolated peptide of SEQ ID NO: 1; and transplanting the isolated organ, tissue, or cell into a recipient.

2. A method for organ, tissue or cell transplantation comprising administering to a donor and/or recipient for organ, tissue or cell transplantation the isolated peptide of SEQ ID NO: 1; isolating an organ, tissue or cell for transplatation from the donor; and transplanting the isolated organ, tissue, or cell into the recipient.

3. The method of claim 2 wherein the peptide is administered in any one or more stages before, after, or during transplantation to the donor or to the recipient.

4. The method of claim 3 comprising administering the peptide through perfusion of an organ, tissue or cells in a donor's or recipient's body with the organ, tissue or cells present in the body.

5. The method according to claim 2 wherein the peptide is administered in a single dose of 1 to 10000 mg based on a 60-kg adult.

6. The method according to claim 2 wherein the daily dose of the administered peptide is 1 μg/kg/day to 10 g/kg/day.

7. A method for organ, tissue or cell transplantation comprising isolating an organ, tissue or cell for transplantation from a donor; contacting the isolated organ, tissue or cells with a composition comprising the isolated peptide of SEQ ID NO: 1; and transplanting the isolated organ, tissue, or cell into a recipient.

8. The method of claim 7 wherein the composition comprises a sufficient amount of the peptide as the active ingredient to strengthen the survivability or function of the organ, tissue, or cells after transplantation into a recipient.

9. The method of claim 8 wherein the composition comprises 10 to 1000 mg/L of the isolated peptide.

10. The method of claim 9 wherein the composition comprises 50 to 500 mg/L of the isolated peptide.

11. The method of claim 7 wherein the composition further comprises phosphate buffered saline (PBS), Collins' solution, and citrate solution.

12. A method for organ, tissue or cell transplantation comprising administering to a donor and/or recipient for organ, tissue or cell transplantation a composition comprising the isolated peptide of SEQ ID NO: 1; isolating an organ, tissue or cell for transplantation from the donor; and transplanting the isolated organ, tissue, or cell into the recipient.

13. The method of claim 12 wherein the composition is administered in any one or more stages before, after, or during transplantation to the donor or to the recipient.

14. The method of claim 12 wherein the composition is administered through oral, intrarectal, transdermal, intravenous, intramuscular, intraperitoneal, bone marrow, intrathecal, or subcutaneous routes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2016
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 040840/0396 →
Priority Claims (2)
KR 10-2014-0052536 · Apr 30, 2014 · national
WO PCT/KR2014/004194 · May 9, 2014 · international
Continuity (1)
Related Publication 20170058001A1 · Mar 2, 2017